Tranylcypromine (2-PCPA) hydrochloride [1986-47-6]

Katalog-Nummer T1025-500mg

Size : 500mg

Marke : TargetMol


Tranylcypromine (2-PCPA) hydrochloride

(Synonyms: Tranylcypromine (2-PCPA) HCl, SKF-385 HCl) Copy Product Info
Tranylcypromine (2-PCPA) hydrochloride (SKF-385 HCl), a Monoamine Oxidase inhibitor, is effective in the treatment of major depression, dysthymic disorder, and atypical depression.
Tranylcypromine (2-PCPA) hydrochloride
Cas No. 1986-47-6
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.97%
Appearance:Solid
Color:White
COA LCMS HNMR

Product Introduction

Bioactivity
Description
Tranylcypromine (2-PCPA) hydrochloride (SKF-385 HCl), a Monoamine Oxidase inhibitor, is effective in the treatment of major depression, dysthymic disorder, and atypical depression.
Targets & IC50
MAO-B:7 μM, LSD1:22.3 μM, MAO-A:11.5 μM
In vitro
Compared with the control group, Tranylcypromine at dosages of 5 mg/kg and 10 mg/kg significantly and gradually increased muscle activity in male rats; however, a 2 mg/kg dosage of Tranylcypromine had no effect. Additionally, Tranylcypromine administered at 10 mg/kg markedly increased the number of copulatory behaviors in male rats.
In vivo
In bovine aortic endothelial cells, Tranylcypromine (500 μg/mL) markedly inhibits bradykinin-induced release of arachidonic acid. Additionally, Tranylcypromine suppresses the activity of CYP2A6 (IC50: 0.42 μM) and CYP2E1 (IC50: 3 μM) in human liver microsomes (HLMs), inducing type II and cyclopropylbenzene type I difference spectra in HLMs. Nicotine metabolism mediated by CYP2A6 in HLMs is completely inhibited by R-(+)-Tranylcypromine (Ki: 0.05 μM), (±)-Tranylcypromine (Ki: 0.08 μM), and S-(-)-Tranylcypromine (Ki: 2.0 μM).
SynonymsTranylcypromine (2-PCPA) HCl, SKF-385 HCl
Kinase Assay
PDE activity is determined with some modifications. The assay mixture contain 50 mM Tris (pH 7.4), 5 mM MgCl2, 0.5 μM cAMP or cGMP, and [3H]cAMP or [3H]cGMP (about 30,000 cpm/assay), the indicated concentration of the inhibitor and an aliquot of the enzyme solution at a final assay volume of 200 μL. Stock solutions of the compounds are diluted 1:100 (v/v) in the Tris buffer mentioned above; appropriate dilutions are prepared in 1% (v/v) DMSO/Tris buffer, which are diluted 1:2 (v/v) in the assays to obtain the desired final concentrations of the inhibitors at a DMSO concentration of 0.5% (v/v). DMSO itself affected none of the PDE activities. After preincubation for 5 min at 37°C, the reaction is started by the addition of substrate (cAMP or cGMP) and the assays are incubated for further 15 min at 37°C. Then 50 μL of 0.2 N HCl is added to stop the reaction and the assays are left on ice for about 10 min. Following incubation with 25 μg of 5′-nucleotidase (Crotalus atrox snake venom) for 10 min at 37°C, the assays are loaded on QAE Sephadex A-25 (1 mL of bed volume in Poly-Prep chromatography columns). The columns are eluted with 2 mL of 30 mM ammonium formate (pH 6.0) and the eluate is counted for radioactivity. Results are corrected for blank values (measured in the presence of denatured protein) that are below 5% of total radioactivity. The amount of cyclic nucleotides hydrolyzed did not exceed 30% of the original substrate concentration[3].
Chemical Properties
Molecular Weight169.66
FormulaC9H11N·HCl
Cas No.1986-47-6
SmilesN[C@H]1[C@H](C2=CC=CC=C2)C1.Cl
Relative Density.no data available
Storage & Solubility Information
StorageStore under nitrogen,Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
H2O: 100 mg/mL (589.41 mM), Sonication is recommended.
DMSO: 250 mg/mL (1473.54 mM), Sonication is recommended.
In Vivo Formulation
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (11.79 mM), Sonication is recommended.
10% DMSO+90% Saline: 10 mg/mL (58.94 mM), Solution.
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
H2O/DMSO
1mg5mg10mg50mg
1 mM5.8941 mL29.4707 mL58.9414 mL294.7071 mL
5 mM1.1788 mL5.8941 mL11.7883 mL58.9414 mL
10 mM0.5894 mL2.9471 mL5.8941 mL29.4707 mL
20 mM0.2947 mL1.4735 mL2.9471 mL14.7354 mL
50 mM0.1179 mL0.5894 mL1.1788 mL5.8941 mL
100 mM0.0589 mL0.2947 mL0.5894 mL2.9471 mL
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.